CEL-SCI : La voix de la raison

jazmin

09 avr. 2012 •08:14

Personne pour réagir pour ou contre le dernier article de Adam F. en date du 5 avril?
Pour ceux qui l'auraient loupé, le voici ci-dessous:
en fait A.F. répond aux justes craintes d'un investisseur parmi d'autres.
Je suis 100% en faveur de cette réponse!
Je présume que les chiffres avancés concernant les "compensations" de l'an dernier reçues par le CEO et l'administrateur sont extraits d'une source sûre.
En Belgique, on se scandalise des "parachutes dorés" accordés aux CEO de grosses compagnies multi-média ou de transport. Que dire quand il ne s'agit dans ce cas-ci que d'une petite biotech pratiquement inconnue?
It's just a scam!

Frank J. asks, "I've read a number of your articles on Cel-Sci(CVM_). Like most others, I was sucked in to all the hype of their 'breakthrough' drug Multikine. However, the more information I read, the more I'm starting to think it's just a scam to reel in retail investors. With all your history on drug stocks, can you please share your knowledge with all of us on whether this is a blockbuster or a bust? Thank you."

I've lost track of how many times I've counseled biotech investors to run screaming from Cel-Sci, which isn't a drug company as much as it's an efficient cash-transfer mechanism from retail investors to the pockets of Cel-Sci's top executives. President Max de Clara made $645,000 in total compensation last year; CEO Geert Kersten cleared $744,000.

Multikine is a bust. If you're new to the Cel-Sci story, I suggest reading my two-part dismemberment of the Multikine phase II study. Part I covers the misleading response rate reported in the study; part II demonstrates the absurdity of a purported Multikine survival benefit, as Cel-Sci still claims to this day.